Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-21

Study Completion Date

2019-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 15 mg in Japanese healthy male subjects aged 20 to 40 years. Rivaroxaban is an approved drug to be used for the prevention of events/diseases caused by blood clots. Currently, there are two formulations of Rivaroxaban available on the market in Japan and they are film-coated tablets and fine granules. To further improve patients' convenience, a new formulation, orally disintegrating tablet (ODT, a drug dosage form designed to be dissolved on the tongue rather than swallowed whole) is under development. The goal of this study was to compare the effect of this new formulation with film-coated tablets when taken with or without water.

Participants in this study received one oral dose of rivaroxaban 15 mg ODT either with or without water and one oral dose of rivaroxaban 15 mg film-tablet. There were at least 5 days between the two doses. Observation for each participant lasted about 6 weeks in total. Blood samples were collected from the participants to measure the blood level of the study drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

NCT04511611

Clinical Pharmacology

COMPLETED PHASE1

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

NCT04753489

Bioequivalence

UNKNOWN PHASE1

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

NCT04424381

Healthy Subjects

COMPLETED PHASE1

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

NCT04720092

Thromboembolic Disorders

COMPLETED PHASE1

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

NCT02367027

Pharmacokinetics

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clinical Pharmacology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test C: 15 mg ODT with water, then 15 mg film-coated tablet

Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state

Group Type EXPERIMENTAL

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Intervention Type DRUG

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Intervention Type DRUG

15 mg as 1 x 15 mg film-coated tablet

Test C: 15 mg film-coated tablet, then 15 mg ODT with water

Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state

Group Type EXPERIMENTAL

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Intervention Type DRUG

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Intervention Type DRUG

15 mg as 1 x 15 mg film-coated tablet

Test D: 15 mg ODT without water, then 15 film-coated tablet

Participants received one single dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban film-coated tablet in the fasted state

Group Type EXPERIMENTAL

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Intervention Type DRUG

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Intervention Type DRUG

15 mg as 1 x 15 mg film-coated tablet

Test D: 15 mg film-coated tablet, then 15 mg ODT without water

Participants received one single dose of 15 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 15 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state

Group Type EXPERIMENTAL

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

Intervention Type DRUG

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Intervention Type DRUG

15 mg as 1 x 15 mg film-coated tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (BAY 59-7939, Xarelto) in ODT form

15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Intervention Type DRUG

Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

15 mg as 1 x 15 mg film-coated tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Japanese healthy male subjects, aged 20 to 40 years (inclusive), with body mass index 17.6 to 26.4 kg/m²

Exclusion Criteria

* Subject with incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal
* Subject with known hypersensitivity to the study drugs (active substances or excipients of the preparations)
* Subject with known coagulation disorders (e.g. von Willebrand disease, hemophilia)
* Subject with febrile illness within 1 week before the first study drug administration
* Subject with suspicion of drug or alcohol abuse
* Subject with intake of foods or beverages containing grapefruit, pomelo, Seville orange, and tangelo within 1 week before the first study drug administration
* Subject with therapies (e.g. physiotherapy, acupuncture, etc.) within 1 month before starting study treatment
* Subject with clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the corrected QT (QTc) interval over 450 msec
* Subject with systolic blood pressure below 90 or above 130 mmHg
* Subject with diastolic blood pressure below 45 or above 85 mmHg
* Subject with clinically relevant deviations of the screened laboratory parameters from reference ranges

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes